Results 1 to 10 of about 67,431 (260)
Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. [PDF]
PLoS ONE, 2014 Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified.
Hiroyuki Sako +9 more
doaj +2 more sources
The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience [PDF]
Vojnosanitetski Pregled, 2021 Background/Aim. The treatment of chronic myeloid leukemia (CML) has changed dramatically with the advent of targeted therapies. This study aimed to assess the efficacy of generic imatinib in CML patients treated in our center. Methods.
Urošević Ivana +9 more
doaj +1 more source
Induction of autophagy has protective roles in imatinib-induced cardiotoxicity
Toxicology Reports, 2021 Cardiotoxicity is one of the severe adverse effects of chemotherapeutic agents. Imatinib was previously reported to induce cardiotoxicity. Autophagy is an intracellular bulk protein and organelle degradation process, but its roles in cardiac diseases are
Miyuki Kobara +3 more
doaj +1 more source
Case Reports in Oncology, 2021 Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse drug reaction; reported cases are sometimes imatinib mesylate induced.
Hyerin Park, Gil-Soon Choi, Eun Mi Lee
doaj +1 more source
The Oncologist, 2007 Learning Objectives After completing this course, the reader will be able to: Identify the current indications for imatinib.Describe the pharmacokinetics of imatinib.Discuss the mechanisms involved in imatinib resistance. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist ...
Christine E, de Kogel +1 more
openaire +3 more sources
Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice. [PDF]
PLoS ONE, 2014 Recent studies indicate that tyrosine kinase inhibitors, including imatinib, can reverse hyperglycemia in non-obese diabetic (NOD) mice, a model of type 1 diabetes (T1D). Imatinib inhibits c-Abl, c-Kit, and PDGFRs.
Janet Lau +5 more
doaj +1 more source
Japanese Journal of Clinical Immunology, 2009 The progress in molecular targeting therapy includes two tides, namely, small molecule compounds and large molecule biological agents. Although the latter prevails in the field of clinical immunology, the former attracts more and more attention in these few years.
+6 more sources
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. [PDF]
PLoS Pathogens, 2015 Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors.
Ruth J Napier +16 more
doaj +1 more source
Frontiers in Pharmacology, 2019 Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters ...
Yi Qian +9 more
doaj +1 more source
Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation. [PDF]
PLoS ONE, 2013 Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR.
Hua Jin +11 more
doaj +1 more source